NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells

References

• Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 2010; 46:1967-78; PMID:20451372; http://dx.doi.org/10.1016/j.ejca.2010.04.004
   PubMed Web of Science ®Google Scholar
• Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365:2041-54; PMID:15950718; http://dx.doi.org/10.1016/S0140-6736(05)66698-6
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66:115-32; http://dx.doi.org/10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Chan AT. Current treatment of nasopharyngeal carcinoma. Eur J Cancer 2011; 47 Suppl 3:S302-3; PMID:21943991; http://dx.doi.org/10.1016/S0959-8049(11)70179-4
   PubMedGoogle Scholar
• Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, Boussen H, Errihani H. Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128:79-85; PMID:21177151; http://dx.doi.org/10.1016/j.anorl.2010.10.003
   PubMed Web of Science ®Google Scholar
• Dugbartey GJ, Peppone LJ, de Graaf IA. An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures. Toxicology 2016; 371:58-66; PMID:27717837; http://dx.doi.org/10.1016/j.tox.2016.10.001
   PubMed Web of Science ®Google Scholar
• Agbale CM, Cardoso MH, Galyuon IK, Franco OL. Designing metallodrugs with nuclease and protease activity. Metallomics 2016; 8:1159-69; PMID:27714031; http://dx.doi.org/10.1039/C6MT00133E
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17:1509-20; PMID:27686945; http://dx.doi.org/10.1016/S1470-2045(16)30410-7
   PubMed Web of Science ®Google Scholar
• Zeng Q, Wang Z, Liu C, Gong Z, Yang L, Jiang L, Ma Z, Qian Y, Yang Y, Kang H, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem 2016; 418:137-46; PMID:27334757; http://dx.doi.org/10.1007/s11010-016-2739-5
   PubMed Web of Science ®Google Scholar
• Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, Yamauchi S, Fukamachi T, Kobayashi H, Tada Y, Takiguchi Y, et al. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 2012; 19:218-28; PMID:22223137; http://dx.doi.org/10.1038/cgt.2011.86
   PubMed Web of Science ®Google Scholar
• Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV, Khochbin S, Bepler G, Zhang X. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 2012; 7:e44265; PMID:22957056; http://dx.doi.org/10.1371/journal.pone.0044265
   PubMed Web of Science ®Google Scholar
• Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213:374-83; PMID:17680632; http://dx.doi.org/10.1002/jcp.21223
   PubMed Web of Science ®Google Scholar
• Wei SC, Fattet L, Yang J. The forces behind EMT and tumor metastasis. Cell Cycle 2015; 14:2387-8; PMID:26083471; http://dx.doi.org/10.1080/15384101.2015.1063296
   PubMed Web of Science ®Google Scholar
• Samatov TR, Tonevitsky AG, Schumacher U. Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer 2013; 12:107; PMID:24053443; http://dx.doi.org/10.1186/1476-4598-12-107
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131-42; PMID:16493418; http://dx.doi.org/10.1038/nrm1835
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90; PMID:19945376; http://dx.doi.org/10.1016/j.cell.2009.11.007
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu H, Xia F, Zhang QW, Zhang YY, Zhao Q, Chao ZH, Jiang ZW, Jiang CC. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int J Mol Med 2014; 33:151-9; PMID:24173500
   PubMed Web of Science ®Google Scholar
• Chan KC, Chan LS, Ip JC, Lo C, Yip TT, Ngan RK, Wong RN, Lo KW, Ng WT, Lee AW, et al. Therapeutic targeting of CBP/beta-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Sci Rep 2015; 5:9979; PMID:25897700; http://dx.doi.org/10.1038/srep09979
   PubMed Web of Science ®Google Scholar
• Jiang Q, Zhou Y, Yang H, Li L, Deng X, Cheng C, Xie Y, Luo X, Fang W, Liu Z. A directly negative interaction of miR-203 and ZEB2 modulates tumor stemness and chemotherapy resistance in nasopharyngeal carcinoma. Oncotarget 2016; 7:67288-301; PMID:27589832
   PubMed Web of Science ®Google Scholar
• Zhang P, Hong H, Sun X, Jiang H, Ma S, Zhao S, Zhang M, Wang Z, Jiang C, Liu H. MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/Notch1/E-cadherin in cisplatin-resistant nasopharyngeal carcinoma cells. Am J Cancer Res 2016; 6:141-56; PMID:27186392
   PubMed Web of Science ®Google Scholar
• Harvey KF, Dinudom A, Komwatana P, Jolliffe CN, Day ML, Parasivam G, Cook DI, Kumar S. All three WW domains of murine Nedd4 are involved in the regulation of epithelial sodium channels by intracellular Na+. J Biol Chem 1999; 274:12525-30; PMID:10212229; http://dx.doi.org/10.1074/jbc.274.18.12525
   PubMed Web of Science ®Google Scholar
• Donovan P, Poronnik P. Nedd4 and Nedd4-2: ubiquitin ligases at work in the neuron. Int J Biochem Cell Biol 2013; 45:706-10; PMID:23262292; http://dx.doi.org/10.1016/j.biocel.2012.12.006
   PubMed Web of Science ®Google Scholar
• Ikeda M, Ikeda A, Longan LC, Longnecker R. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology 2000; 268:178-91; PMID:10683340; http://dx.doi.org/10.1006/viro.1999.0166
   PubMed Web of Science ®Google Scholar
• Cao XR, Lill NL, Boase N, Shi PP, Croucher DR, Shan H, Qu J, Sweezer EM, Place T, Kirby PA, et al. Nedd4 controls animal growth by regulating IGF-1 signaling. Sci Signal 2008; 1:ra5; PMID:18812566; http://dx.doi.org/10.1126/scisignal.1160940
   PubMed Web of Science ®Google Scholar
• Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007; 128:129-39; PMID:17218260; http://dx.doi.org/10.1016/j.cell.2006.11.039
   PubMed Web of Science ®Google Scholar
• Sun A, Yu G, Dou X, Yan X, Yang W, Lin Q. Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis. Mol Cancer 2014; 13:248; PMID:25395181; http://dx.doi.org/10.1186/1476-4598-13-248
   PubMed Web of Science ®Google Scholar
• Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, Jeong SY, Hwang JJ, Lee SJ, Suh YA, et al. p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ 2014; 21:146-60; PMID:24141722; http://dx.doi.org/10.1038/cdd.2013.141
   PubMed Web of Science ®Google Scholar
• Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, Botti G, Pirozzi P, Rocco G, De Rosa N, et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 2010; 177:2622-34; PMID:20889565; http://dx.doi.org/10.2353/ajpath.2010.091075
   PubMed Web of Science ®Google Scholar
• Jung S, Li C, Jeong D, Lee S, Ohk J, Park M, Han S, Duan J, Kim C, Yang Y, et al. Oncogenic function of p34SEI-1 via NEDD41mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway. Int J Oncol 2013; 43:1587-95; PMID:23970032
   PubMed Web of Science ®Google Scholar
• Zou X, Levy-Cohen G, Blank M. Molecular functions of NEDD4 E3 ubiquitin ligases in cancer. Biochim Biophys Acta 2015; 1856:91-106; PMID:26116757
   PubMed Web of Science ®Google Scholar
• Ye X, Wang L, Shang B, Wang Z, Wei W. NEDD4: a promising target for cancer therapy. Curr Cancer Drug Targets 2014; 14:549-56; PMID:25088038; http://dx.doi.org/10.2174/1568009614666140725092430
   PubMed Web of Science ®Google Scholar
• Liu J, Wan L, Liu P, Inuzuka H, Liu J, Wang Z, Wei W. SCF(beta-TRCP)-mediated degradation of NEDD4 inhibits tumorigenesis through modulating the PTEN/Akt signaling pathway. Oncotarget 2014; 5:1026-37; PMID:24657926; http://dx.doi.org/10.18632/oncotarget.1675
   PubMed Web of Science ®Google Scholar
• Zeng T, Wang Q, Fu J, Lin Q, Bi J, Ding W, Qiao Y, Zhang S, Zhao W, Lin H, et al. Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis. Cell Rep 2014; 7:871-82; PMID:24746824; http://dx.doi.org/10.1016/j.celrep.2014.03.045
   PubMed Web of Science ®Google Scholar
• Salah Z, Cohen S, Itzhaki E, Aqeilan RI. NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation. Cell Cycle 2013; 12:3817-23; PMID:24107629; http://dx.doi.org/10.4161/cc.26672
   PubMed Web of Science ®Google Scholar
• Zheng MZ, Qin HD, Yu XJ, Zhang RH, Chen LZ, Feng QS, Zeng YX. Haplotype of gene Nedd4 binding protein 2 associated with sporadic nasopharyngeal carcinoma in the Southern Chinese population. J Transl Med 2007; 5:36; PMID:17626640; http://dx.doi.org/10.1186/1479-5876-5-36
   PubMed Web of Science ®Google Scholar
• Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, Lo KW. Etiological factors of nasopharyngeal carcinoma. Oral Oncol 2014; 50:330-8; PMID:24630258; http://dx.doi.org/10.1016/j.oraloncology.2014.02.006
   PubMed Web of Science ®Google Scholar
• Gu MF, Liu LZ, He LJ, Yuan WX, Zhang R, Luo GY, Xu GL, Zhang HM, Yan CX, Li JJ. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma. Int J Cancer 2013; 132:215-23; PMID:22610788; http://dx.doi.org/10.1002/ijc.27638
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, Chen C, Yang Y, Miele L, Sarkar FH, et al. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget 2013; 4:1999-2009; PMID:24158561; http://dx.doi.org/10.18632/oncotarget.1471
   PubMed Web of Science ®Google Scholar
• Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X, Chen S, Chen C, Wang Z. Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer 2014; 110:1958-67; PMID:24642627; http://dx.doi.org/10.1038/bjc.2014.136
   PubMed Web of Science ®Google Scholar
• Chen DJ, Chen W, Jiang H, Yang H, Wang YC, Chen JH. Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial-mesenchymal transition. Drug Des Devel Ther 2016; 10:2845-53; PMID:27660415; http://dx.doi.org/10.2147/DDDT.S101998
   PubMed Web of Science ®Google Scholar
• Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H, Lu W. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget 2016; 7:24510-26; PMID:27014910
   PubMed Web of Science ®Google Scholar
• Liao CJ, Chi HC, Tsai CY, Chen CD, Wu SM, Tseng YH, Lin YH, Chung IH, Chen CY, Lin SL, et al. A novel small-form NEDD4 regulates cell invasiveness and apoptosis to promote tumor metastasis. Oncotarget 2015; 6:9341-54; PMID:25823820; http://dx.doi.org/10.18632/oncotarget.3322
   PubMed Web of Science ®Google Scholar
• Zhou W, Xu J, Zhao Y, Sun Y. SAG/RBX2 is a novel substrate of NEDD4-1 E3 ubiquitin ligase and mediates NEDD4-1 induced chemosensitization. Oncotarget 2014; 5:6746-55; PMID:25216516; http://dx.doi.org/10.18632/oncotarget.2246
   PubMed Web of Science ®Google Scholar
• Li JJ, Wang R, Lama R, Wang X, Floyd ZE, Park EA, Liao FF. Ubiquitin Ligase NEDD4 Regulates PPARgamma Stability and Adipocyte Differentiation in 3T3-L1 Cells. Sci Rep 2016; 6:38550; PMID:27917940; http://dx.doi.org/10.1038/srep38550
   PubMed Web of Science ®Google Scholar
• Hang X, Zhu S, Di H, Wu Z, Chu K, Wang J, Xin H, Yu G, Peng H, Miao X, et al. NEDD4 Depletion Inhibits Hepatocellular Carcinoma Growth via Targeting PTEN. Cell Physiol Biochem 2016; 39:768-79; PMID:27467187; http://dx.doi.org/10.1159/000445667
   PubMed Web of Science ®Google Scholar
• Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res 2012; 1:88-9; PMID:23002429
   PubMed Web of Science ®Google Scholar
• Xu C, Fan CD, Wang X. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase. Oncogene 2015; 34:281-9; PMID:24413081; http://dx.doi.org/10.1038/onc.2013.557
   PubMed Web of Science ®Google Scholar
• Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ 2013; 20:503-14; PMID:23175188; http://dx.doi.org/10.1038/cdd.2012.147
   PubMed Web of Science ®Google Scholar
• Huang Z, Choi BK, Mujoo K, Fan X, Fa M, Mukherjee S, Owiti N, Zhang N, An Z. The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling. Oncogene 2015; 34:1105-15; PMID:24662824; http://dx.doi.org/10.1038/onc.2014.56
   PubMed Web of Science ®Google Scholar
• Lu C, Thoeni C, Connor A, Kawabe H, Gallinger S, Rotin D. Intestinal knockout of Nedd4 enhances growth of Apcmin tumors. Oncogene 2016; 35:5839-49; PMID:27086928; http://dx.doi.org/10.1038/onc.2016.125
   PubMed Web of Science ®Google Scholar
• Qu MH, Han C, Srivastava AK, Cui T, Zou N, Gao ZQ, Wang QE. miR-93 promotes TGF-beta-induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells. Tumour Biol 2016; 37:5645-51; PMID:26581907; http://dx.doi.org/10.1007/s13277-015-4328-8
   PubMed Web of Science ®Google Scholar
• Quirit JG, Lavrenov SN, Poindexter K, Xu J, Kyauk C, Durkin KA, Aronchik I, Tomasiak T, Solomatin YA, Preobrazhenskaya MN, et al. Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells. Biochem Pharmacol 2017; 127:13-27; PMID:27979631; http://dx.doi.org/10.1016/j.bcp.2016.12.007
   PubMed Web of Science ®Google Scholar
• Wang L, Ye X, Cai X, Su J, Ma R, Yin X, Zhou X, Li H, Wang Z. Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells. Oncotarget 2015; 6:18027-37; PMID:26046466; http://dx.doi.org/10.18632/oncotarget.4090
   PubMed Web of Science ®Google Scholar